More M&A For Astellas As It Pursues New Mid-Term Goals?
This article was originally published in PharmAsia News
Astellas's new mid-term business plan envisages mid-single-digit sales growth for the company over the next two years, with new products in oncology and urology the main drivers of the expected increase and further acquisitions seemingly on the cards. The firm has also just set up a new U.S. joint venture to pursue R&D in new therapeutic areas.
You may also be interested in...
Astellas’s overactive bladder drug mirabegron, which previously failed to pass muster in India, has now been cleared by an expert panel in the country, though competition appears to be building up alongside.
Join us for a brief audio tour around the past week's major global biopharma industry developments, in this podcast version of Scrip's Five Must-Know Things.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.